Floatz Rating
CC43/100
Confidence
Indicative
Sponsor
Toray Industries, Inc
Modality
monoclonal_antibody
Development Phase
Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
28Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT03872947CT.gov A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors | — | Active Not Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95Moderate confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Skin Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Monoclonal Antibody Trk-950 (this asset) | Toray Industries, Inc | P1 | CC · 43 |
| Prednisone | Dana-Farber Cancer Institute | P4 | BBB |
| Cyclophosphamide | Institute of Oncology Ljubljana | P2 | BB |
| Sirolimus | Dana-Farber Cancer Institute | P4 | BB |
| Nivolumab | 7 Hills Pharma, LLC | P3 | BB |
| Fludarabine | H. Lee Moffitt Cancer Center and Research Institute | P2 | BB |
| Cis-Diamminedichloroplatinum Ii | Toray Industries, Inc | P3 | BB |
| Vinblastine | Memorial Sloan Kettering Cancer Center | P3 | BB |
| Dacarbazine | Memorial Sloan Kettering Cancer Center | P3 | BB |
+41 more in the Skin Cancer cohort
Other indications for Monoclonal Antibody Trk-950
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Melanoma | — | P1/2 | CC · 46 |
| Neoplasm | — | P1/2 | CC · 45 |
| Cholangiocarcinoma | — | P1 | CC · 42 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Monoclonal Antibody Trk-950 in Skin Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/monoclonal-antibody-trk-950-skin-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →